(WASHINGTON, D.C.) – In coordination with the Trump Administration and Centers for Medicare and Medicaid Services (CMS) Administrator Dr. Mehmet Oz, today the Pharmaceutical Care Management Association (PCMA) and its members announced a new commitment related to TrumpRx:

“The following Pharmacy Benefit Managers, in conjunction with PCMA, the Pharmaceutical Care Management Association, commit to supporting the goals of transparency and affordability by presenting to patients the cash prices listed on TrumpRx for comparison to the prices under their benefit, through use of PBM real time benefit tools, when consistent with plan coverage and allowed by law.”

This means consumers and patients who have pharmacy benefits provided by these companies will be able to see TrumpRx prices when comparing costs through their plan-based real-time benefit tools or other cost transparency platforms that the individual companies operate.

David Marin, President and CEO of PCMA, made the following statement about this news:

“Consumers and patients are better off when they have more options and a clear view of their costs. If there are times when a product is cheapest on TrumpRx, patients should know that. This administration has embraced the use of real-time benefit tools to give patients more information, and we strongly embrace this technology. This commitment will allow consumers to compare options and make better informed choices about costs and where they access prescription drugs. It’s a no-brainer for our industry and for American families.”

PCMA Member Companies:

CarelonRx

CVS Health

Express Scripts

Humana

MedImpact Healthcare Systems

Navitus Health Solutions

OptumRx

Prime Therapeutics

VytlOne

Welldyne